Drugs / gp160 MN/LAI-2
last change May 2005 re-read 2 minutes ago

gp160 MN/LAI-2

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1 · a red edge is where a trial was stopped

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT00031109 ? → May 2005 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as gp160 MN/LAI-2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00031109
Modality Vaccine “recombinant gp160MN/LAI-2 vaccineNCT00031109